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Since the discovery of dendrimers in 1978, it has received serious attention as a drug carrier 
polymer most especially in cancer chemotherapeutics where precision and targeted delivery 
of drug to tumor cells is most desirable. Dendrimers are mostly synthetic, hyper-branched, 
tree-like globular, nano-sized polymers with excellent physicochemical properties that can be 
utilized in the formulation, design and delivery of drugs, vaccine and genes to specific 
receptors in the body.  This review focused on the synthesis, types and applications of 
dendrimers in the delivery of cytotoxic drugs. The review shows that in the last decade, 
dendrimers have proved to be promising nanocarriers for various drugs including anti-
inflammatory, antimicrobial, and anticancer drugs. The application of dendrimers as scaffolds 
of prodrugs is particularly interesting. Dendrimers are relatively more stable compared with 
other nano drug carriers and  are suitable in formulating drugs for different routes of 
administration.  As more and newer dendrimers are introduced into the market, they will have 
increasing role in therapeutic delivery of drugs, vaccines and gene. 
 




Dendrimers are three dimensional polymers 
with unique features such as, hyper-branched, 
tree- like, globular structure, nanoscopic size, 
narrow polydispersity index, and excellent 
controlled molecular structure. Dendrimers are 
particularly interesting as they are relatively 
more stable when compared to other nano 
drug carriers.  They also feature prominently in 
the design and fabrication of targeted drug 
delivery systems, which selectively deliver 
therapeutic agents to receptor sites and 
organs in the body.  Dendrimer architecture 
can be distinguished easily from other 
nanoscopic polymers as they possess multiple 
functional groups at the periphery and interior 
lipophilic cavity which invariably contribute to 
the increasing solubility of hydrophobic drugs 
(Kesharwani et al., 2014). Formulation 
possibilities such as incorporation of both 
lipophilic and hydrophilic drugs substances 
within the same dendrimer and conjugation of  
drug molecule  with the dendrimer peripheral 
multi functional groups are just but few of the 
numerous advantages offered  by dendrimer 
based nanopharmaceuticals (Bhadra et al., 
2005).   
 
The first dendrimer was synthesized in 1978, 
and the word dendrimer originated from two 
Greek words, “Dendron”, meaning tree and 
“meros” meaning part. Dendrimers can also be 
defined as synthetic, biodegradable and 
biocompatible macromolecules characterized 
by high branching points, three dimensional 
globular shape, monodispersity and 
nanometric size range (Kono et al.,1999; Dutta 
et al., 2006). There are three basic 
architectural components of a dendrimer  as 
shown in Figure 1,  (i) Interior core (ii) Interior 
layers composed of repeating units radically 
attached out of interior core (also refers to as 
the generations (iii) Exterior (terminal 
functionality) attached to outermost interior 
generation, the ligands (Surendra et al.,2014). 
 
 








Methods of fabricating dendrimers 
The first synthesized dendrimer was 
polyamidoamines (PAMAM), also known as 
Starbust® dendrimers. The term Starbust®   is a 
trademark of the Dow Chemicals Company. 
Basically, there are two approaches that may 
be used to synthesize dendrimers; divergent 
and convergent methods. Divergent method 
starts from the central core and extends 
outward toward the periphery, i.e. the 
dendrimer grows outwards from a 
multifunctional core molecule. The core 
molecule reacts with monomer molecules 
containing one reactive and two dormant 
groups giving the first generation dendrimer. 
Higher generations with higher molecular 
weights can be generated by activating the 
new periphery of the molecule for reactions 
with more monomers. The stepwise reaction 
can be repeated to obtain dendrimers of 
different generations. The divergent approach 
is very useful in the production of large 
quantities of high generations of dendrimers. 
The problem of side reactions and incomplete 
reactions of the end groups leading to 
structural defects are common in divergent 
method, however these problems can be 
solved by addition of excess reagents. 
Purification may also become an issue at the 
end of the reaction (Pushkar et al., 2006; 
Sakthivel et al.,1998). 
 
The convergent method uses a top–down 
approach; it starts from the periphery of 
dendrimer, and grows inward to the inner core. 
The convergent method was developed as a 
response to the weaknesses of the divergent 
synthesis. In the convergent approach, the 
dendrimer is constructed stepwise, starting 
from the end groups and progressing inwards. 
When the growing branched polymeric arms, 
called dendrons, are large enough, they are 
attached to a multifunctional core molecule. 
The convergent growth method has several 
advantages, among which are the simplicity of 
purification of  the desired product and 
minimization of  the occurrence of structural 
defects in the final structure. It is also possible 
to introduce subtle engineering into the 
dendritic structure by precise placement of 
functional groups at the periphery of the 
macromolecule. The convergent approach  
however, does not allow the formation of high 
generations  dendrimers because  of  high 
incidence of  steric problem, which occurs  
during  the synthesis (Hawker and Frechet, 
1990;Tomolia, et al., 2005).  
 
Each method has distinct advantages and 
disadvantages, and the selection of an 
appropriate route to generate a desired 
dendrimer depends mainly on the desired 
structure and generation type. While the 
divergent method is suitable for constructing 
high generation dendrimers, the convergent 
method is only suitable for synthesis of low 
molecular weight dendrimers. 
 
Moat commercially available dendrimers such 
as polyamidoamine (PAMAM), poly (propylene 
imine) (PPI), poly-L-lysine, melamine, poly 
(etherhydroxylamine) (PEHAM) poly 
(esteramine) (PEA) and polyglycerol are 
synthesized by divergent method and are 
explored today as drug delivery vehicles 
(Wolinsky  and  Grinstaff 2008; Mintzer  and  
Grinstaff,  2011).  
 
Types of dendrimers 
 
PAMAM dendrimer 
All the generations of polyamidoamines 
(PAMAM) dendrimers are synthesized by the 
divergent pathway, starting with ammonia or 
ethylenediamine as the initiator core reagents. 
PAMAM dendrimers are commercially 
available from G1 to G9. G1 also called 
generation one represent dendrimers with low 
molecular weight, while generation nine (G9) 
are high molecular weight dendrimers usually 
presented as methanol solutions (Hawker & 
Frechet, 1990). The synthesis of PAMAM 
dendrimers starts with the Michael addition 
between the multifunctional central core 
(usually, ammonia or ethylenediamine) and 
methyl acrylate. The shape of these PAMAM 
dendrimers may vary with their generations. 
Low generation PAMAM dendrimers (G1–G3) 
have ellipsoidal shapes, whereas the high 
generations PAMAM, (G4–G10) have  well-
defined cavities and roughly spherical shapes 
(Kim et al., 1998). Generally, G3 PAMAM 
dendrimers are considered more suitable as 
potential nanocarriers for poorly water soluble 
drugs (Ooya et al., 2004).  Amine terminated 
PAMAM dendrimers could be useful in 
transporting drugs across various biological 
membranes, possibly by paracellular and 
endocytostic pathways. Moreover, by 
optimizing the size and surface charge, these 
dendritic platforms can be developed into oral 
delivery system for some orally inactive 
cytotoxic drugs. The various generations of 
PAMAM dendrimers, their molecular weight 









Table 1: Generations of PAMAM, their 








G1 1430 8 
G2 3256 16 
G3 6909 32 
G4 14215 64 
G5 28826 128 
G6 58048 256 
G7 116,493 512 
G8 233,383 1,024 
G9 467,162 2,048 
 
PPI dendrimers 
Poly (propylene imine) dendrimers are poly-
alkyl amines, having primary amines as end 
groups, the dendrimer interior consists of 
numerous tertiary tris-propylene imines. Just 
like PAMAM, PPI dendrimers are commercially 
available from G1 to G5 generations, and have 
found widespread applications in biomedical, 
cosmetic, food and pharmaceutical industries. 
It is widely available as Astramol®.   
 
PPI dendrimers closely resemble PAMAM 
dendrimers except that the repeating units 
may create an internal environment with 
different polarity. The alkyl chain in PPI makes 
the internal microenvironment less polar 
compare to PAMAM dendrimers which have 
amido group as the repeating units (Richter-
Egger et al, 2001). 
 
Other dendrimers described in the literatures 
are Tecto, Multilingual and Frechet 
dendrimers. A dendrimer core with other 
functionally different dendrimers attached to 
the core such that each of the peripheral 
(attached)  dendrimers perform different 
functions such as, tumor cell recognition, 
diagnosis of disease state, drug delivery, 
reporting outcomes of therapy  is referred to 
as  Tecto dendrimer, while Multilingual 
dendrimers,  surfaces contains multiple 
copies of  the same functional groups. 
 
Frechet-Type Dendrimers were first 
developed by Hawker and Frechet. The 
synthesis is based on poly-benzyl ether hyper-
branched skeleton. These dendrimers usually 
have carboxylic acid groups as the surface 
groups, these carboxylic acid groups may 
serves as a good anchoring point for further 
surface functionalisation, and as polar surface 
groups to increase the solubility of this 
hydrophobic dendrimer type in polar solvents 
(Yiyun et al., 2008, Hawker, 2006). 
 
Designing a dendrimer based nanoparticle 
for drug delivery 
All PAMAM dendrimers, which fulfill most 
requirements for use in-vivo applications are 
being considered extensively for targeted drug 
delivery (Tomalia et al., 1985). PAMAM 
dendrimers are also being investigated as 
carriers in gene transfection (Kukowska-
Latallo et al., 1996). The internal tertiary 
amines of PAMAM dendrimers are available 
for acid–base interactions and hydrogen 
bonding as well as for other non-covalent 
interactions with encapsulated guest 
molecules, thus making the polymers effective 
agents for solubilizing hydrophobic drugs 
(Twyman, et al., 1999; Liu, et al., 2000). 
 
Encapsulation is one of the methods used by 
various researchers to formulate dendrimer 
base drug delivery systems. Encapsulation of 
drugs uses the steric bulk of the exterior of the 
dendrimer and interactions between the 
dendrimer and the drug to trap the drug inside 
the dendrimer, Fig. 2. 
 
Dendrimer-drug conjugates, however, have 
the drug attached to the exterior of the 
dendrimer. Most of these conjugates are 
prodrugs and are inactive or have decreased 
activity relative to the free drug. 
  
 
Figure 2: Encapsulation of drug into dendrimer core 





Conjugation refers to covalent attachment of 
free drug to the dendrimer.Dendrimer-drug 
conjugate offers two basic advantages as 
compared to entrapment,   
 Prolong life time of drug in biological 
circulation. 
 Improved  drug  stability 
 
Drug-dendrimer conjugation is aimed at 
exploiting a well-defined multivalent aspect of 
dendrimers, which allows the attachment of 
drug molecules to its periphery. The resultant 
complexes are formed either due to the 
electrostatic interactions between the drug and 
dendrimer or conjugation of the drug to 
dendrimer molecule through electrostatic 
interactions (Zhou et al., 2005). Various 
ionizable drugs form complexes with the large 
number of ionizable terminal surface groups of 
dendrimers. For example, both primary amine 
and tertiary amine groups present on the 
surface of PAMAM dendrimers, offer potential 
sites for drug interactions. Adriamycin and 
methotrexate have been shown to form stable 
complexes through electrostatic interactions 
(Zhou et al., 2005). Moreover, the drugs can 
be covalently conjugated to dendrimers 
through some spacers that may include PEG, 
p-amino benzoic acid, p-amino hippuric acid 
and lauryl chains etc., or biodegradable 
linkages such as amide or ester bonds. This 
prodrug approach has been found to increase 
the stability of drugs and has affected their 
release kinetics significantly. Several 
researchers have successfully conjugated 
many anticancer drugs  such as  cisplatin, 
doxorubicin,  epirubicin, methotrexate and 
paclitaxel with PAMAM dendrimers. The 
results have shown the enhanced solubility 
and controlled release of drugs from these 
complexes in comparison to the pure drug 
(Kaminskas et al., 2012; Gurdag, et al.,  2006). 
Dendrimer-drug conjugates have been 
reported as a potential platform for a combine 
uses as diagnostic and therapeutic agents. 
Such combination of both diagnostic and 
therapeutic agent in a single dendrimer is 
termed theranostic drug delivery system.  
 
Problems associated with the 
administration of cytotoxic agents  
The success of all cytotoxic drugs depends on 
the consistent availability of adequate quantity 
of cytotoxic agents in various tumor cells. After 
the administration of conventional anticancer 
drugs, they are distributed blindly throughout 
the whole body via the bloodstream. They 
affect both malignant and rapidly dividing 
normal living cells of the bone marrow, 
lymphoid tissue, supermatogenic cells, fetus 
as well as hair follicles (Links et al., 1999). 
This account for severe side effects 
associated with the use of most convection 
cytotoxic drugs. Other problems associated 
with the use of cytotoxic agents are,  high 
patient risks, repeated treatments, altered bio-
distribution of drug and the acquisition of 
multidrug resistance (MDR) by the cancer cells 
(Brigger et al., 2002). Since most cancer 
chemotherapies lack specificity and selectivity,  
incorporation of ligands on dendrimer surfaces  
is one of the methods  utilized to effect target 
delivery of anticancer molecules to the  tumor 
cells, thereby reducing  adverse drug effects 
associated with the administration of some of 
these chemotherapeutic drugs (Jain 2005; 
Ould et al 2005; Kipp, 2004). 
 
Acquisition of drug resistance by cancer cells 
is another factor.  Resistance to cytotoxic 
agents could be acquired through both non-
cellular as well as cellular mechanism. The 
non-cellular resistance occurs due to poorly 
vascularized tumor regions which can 
effectively reduce drug access to the tumor 
and thus protect cancerous cells from 
cytotoxicity. The acidic environment in the 
tumors cells can also confer a resistance 
mechanism against alkaline cytotoxic drugs. 
These compounds undergo ionization, thereby 
preventing their diffusion across cellular 
membrane. High interstitial pressure and low 
microvascular pressure may also retard or 
impede extravasation of molecules.  
 
The cellular mechanism of resistance involves 
over expression of the plasma membrane P-
glycoprotein (P-gp), which is capable of 
repelling drugs from the tumor cells, thereby 
leading to a decreased cell sensitivity and 
intracellular accumulation of drugs. This is 
more pronounced with drugs which enters the 
cell by passive diffusion through lipid bilayer. 
Upon entering into cell, these drugs bind to P-
gp, which forms transmembrane channels and 
uses the energy of ATP hydrolysis to pump 
these compounds out of cells (Krishna et al., 
2000).    
 
Co-administration of P-gp inhibitors with 
encapsulated anticancer drugs in 
nanoparticles have been proposed to prevent 
P-gp-mediated multi drug resistance (MDR) 
(Krishna et al., 2000). Other limitations  
include  reduced  potency observed, in some 
drugs after  linkage to targeting moieties when 
targeting portion is not cleaved correctly 




(Krishna, et al., 2000). Rapid blood clearance 
by the reticuloendothelial system (RES) is 
another major problem in cancer therapeutics. 
The RES is part of the natural body defense 
mechanism of which monocytes and 
macrophages located in reticular connective 
tissue (the spleen), are responsible for 
attacking and  removing cellular debris, 
pathogens and foreign substances from the 
bloodstream through phagocytosis.  
Formulation parameters such as particle size, 
hydrophobicity, surface charge and 
composition of the nano particle formulation 
influence the clearance profile of the delivery 
system. RES problem can be overcome by 
PEGylation (attachment of polyethylene glycol 
to the drug carriers). PEGylation has also 
been proposed for other delivery systems in 
order to reduce their clearance by 
reticuloendothelial system (Klibanov et al., 
1990 and Blume et al., 1990).  
 
Tumor Targeting with dendrimer based 
drug delivery system 
Drug targeting is a concept that aims to 
directly deliver therapeutic agents to a specific 
site, cell type, tissue or organ in the body. This 
is extremely beneficial in cancer 
chemotherapeutics where cytotoxic drugs that 
kill tumor cells may also kill or adversely 
damage healthy living tissue as a result of 
indiscriminate distribution of drugs to different 
tissues and organs in the body.  
 
In cancer therapy several approaches have 
been proposed to achieve selective delivery of 
drugs to tumor cells while sparing normal 
healthy cells. One method employs the 
enhanced permeability and retention (EPR) 
phenomenon in tumors where 
microvasculature system becomes more 
permeable and allows accumulation of drug 
molecules selectively in the cancer cells 
(Maeda et al., 2000; Ihre et al., 2002).  In EPR 
targeting, since the therapeutic agents are 
selectively absorbed into the tumor cells, it 
effectively kills the cancer cells with minimal 
effect on normal healthy cells and tissues  
(Padilla De Jesus et al., 2002). 
 
Another useful approach utilizes tumor cells 
specific antigens. Normally, tumor cells 
express or over-express unique receptors or 
antigens. Once identified, they can be targeted 
using specific antibodies, small molecules or 
peptides that can recognize and bind to these 
tumor expressed antigen. In this approach, 
therapeutic or bioactive agents are coupled 
directly to targeting moiety for selective 
delivery. However, there are limitations such 
as decreased solubility, and limited drug 
carrying capability, posed by some of these 
conjugates. There are ongoing investigations 
to design novel carrier systems that can 
overcome these problems, i.e. ensures longer 
circulation times and increased the potential to 
carry larger amounts of drug. One of the aims 
of this approach is to ensure that 
macromolecules that are used as drugs 
carriers remain soluble and bind effectively 
both therapeutic and targeting ligands until 
they reach the targeting sites. Any degradation 
of the carrier or premature release of free drug 
before reaching the desired location defeats 
the purpose of this delivery system.  For this 
reason, a stable and reliable system is most 
desired. Nano-scale dendrimers have been 
proposed and investigated as an effective 
carrier for anti cancer drug targeting (Langer, 
1990; Newkome, et al., 2001; Frechet and 
Tomalia, 2001). 
 
Some clinically useful dendrimer nano-
formulations  
Dendrimers offer various formulation 
possibilities, among which is their ability to 
incorporate two or more drugs within the same 
polymer. Various generations of PAMAM 
dendrimers having PEG grafts were 
synthesized and evaluated for their ability to 
encapsulate two different anticancer drugs: 
Adriamycin (ADC) and methotrexate (MTX). It 
was shown that encapsulation efficiency 
increases with increases in both  PAMAM 
generations and the molecular weight of the 
attached PEG. It was also inferred from the 
study that the increased encapsulation 
efficiency of MTX by dendrimer was due to 
acid-base interaction between MTX (acidic) 
and amino groups of dendrimer polymer 
(Kojima et al., 2000) 
 
A PEGylated-PAMAM (G-4) formulation of 5-
fluorouracil (5-FU) was reported to reduce 
therapeutic side effects, normally experienced 
after administration of convectional 5-
fluorouracil. This formulation also display low 
hemolytic toxicity, high drug loading capacity, 
increased cytotoxicity and improved tumor 
cells permeability.  It was also observed that  
after intravenous administration of different 
formulations of 5-FU to rats through the caudal 
vein, the maximum drug concentration (Cmax) 
from free drugs, nonPEGylated dendrimers, 
and PEGylated dendrimers, was 200–220, 21–
23, and 6-7 mg/mL, respectively. It was only in 
the PEGylated dendrimers formulation that the 
blood level of 5-FU was detectable for up to 12 
h after the administration of the drug (Bhadra 
et al., 2003). 





A  Fifth generation of PAMAM formulation of 
methotrexate was found to be more effective 
in killing tumor cells by conjugating  MTX to 
PAMAM-fluorescein isothiocyanate -folic acid 
complex (PAMAM-FITC-FA) via amide and 
ester linkages. The conjugates were 
internalized in the KB cell line of human 
epidermoid carcinoma. The plain MTX was 
found to be less effective in killing tumor cells 
when compare to drug conjugates through 
ester linkages (Quintana et al., 2002). 
 
Patri and coworkers synthesized G5 PAMAM-
FA-MTX complex. They however modified the 
surfaces of a second batch so that negatively 
charged (carboxylate) groups were obtained 
as terminal functionalities. Binding 
characteristic of all the modified dendrimers 
incorporating MTX with and without FA were 
performed on FR (+) KB cells. The results 
shows a decrease in non-specific interaction of 
the dendrimers as compared to amine 
terminated ones and a greater accumulation of 
the complex in FR (+) cells, which is further 
supported by lack of cytotoxicity in FR(-) cells 
(Patri et al., 2005). 
 
A conjugate of PAMAM dendrimers and 
cisplatin, (a potent anti-cancer drug with 
nonspecific toxicity and poor solubility) was 
equally investigated. The conjugate shows 
increased solubility, decreased systemic 
toxicity and enhanced permeation and 
retention properties (Malik et al., 1999). 
Intravenous administration of this conjugate to 
mice bearing B16F10 tumors was able to 
selectively accumulate cisplatin in solid tumors 
(50-fold increase compared to that achieved 
after intravenous administration of  plain 
cisplatin at its maximum tolerated dose). 
 
Cationic dendrimers were evaluated for 
Deoxyribonucleic acid (DNA), Ribonucleic acid 
(RNA) and microRNA (miRNA) delivery, and 
this has become routine tools in cell biology 
and many other biomedical fields.  
 
It has been reported that intravenous 
administration of G9 PAMAM dendrimer-
complex pCF1CAT plasmid into rats could 
result in high levels of gene expression in the 
lung tissues (Kukowska-Latallo et al., 1996).  
In order to enhance the transfection efficiency 
and expression pattern of the dendrimer, a 
cyclodextrin was conjugated on the surface of 
G3 PAMAM dendrimer. And after the 
intravenous administration of this hybrid 
material and DNA complex into the rats, they 
found that the organ where the transgene 
dominantly expressed was in the spleen 
(Kihara et al.,2005). 
 
Based on this study, mannose was conjugated 
to this hybrid material and this new multi-
functional material was used as a new gene 
transfection agent. After the intravenous 
injection, the hybrid material bearing mannose 
ligands showed higher transfection activity in 
the kidney than dendrimer alone and the 
hybrid material without mannose ligands  
(Kukowska-Latallo et al., 1996 ; Kihara et 
al.,2005 ; Wada et al.,2003). 
 
Various modified PPI dendrimers were 
evaluated as effective transfection agents for 
catalytic DNA enzymes. The results showed 
that intravenous administration of G4 PPI 
dendrimer-PEG conjugate and DNA complex 
into Nude mice could lead to a high gene 
transfection efficacy and nuclear uptake. 
Based on these results, it was concluded that 
dendrimers were promising gene vectors with 
higher capability to deliver gene into the liver, 
spleen, lung, kidney, and even the tumor at 
therapeutic levels, and the intravenous 
administration route may be more suitable 
(Tack et al., 2006). 
 
Oral drug delivery studies using the human 
colon adenocarcinoma cell line (Caco-2) have 
indicated that low generation PAMAM 
dendrimers cross cell membranes, presumably 
through a combination of two processes; 
paracellular transport and adsorptive 
endocytosis. Remarkably, the P-glycoprotein 
efflux transporter does not appear to affect 
dendrimers, therefore drug dendrimer 
complexes are able to bypass the efflux 
transporter. PAMAM dendrimers conjugated 
with folic acid and fluorescein isothiocyanate 
were use for targeting and imaging tumor cells 
respectively (Barbara & Maria, 2001, 
Rajeshbabu et al., 2010). Some clinically 
relevant dendrimer based anticancer drug 












Table 2: Some commercially available dendrimer based anticancer formulations 
 
Drugs                               Dendrimer                          Therapeutic Improvement 
                                         Polymer used 
Methotrexate                 G2.5 and G3 PAMAM            24‑fold increment in cytotoxicity 
Paclitaxel                       Polyglycerol                            Increased aqueous solubility 
                                       (G4 and G5)  
                                       G4 PAMAM                           Increased aqueous solubility      
                                                                                          
10‑hydroxy                    Carboxylated poly                   High cytotoxicity 
camptothecin                 (glycerolsuccinic acid) 
                                                 
        
5‑Fluorouracil                G4 PAMAM                            Targeted drug delivery 
Etoposide                       G4 and G5PAMAM                High loading capacity 
Doxorubicin                   G4 PAMAM                            Improved cytotoxicity 
Doxorubicin                   G5 polylysine                           Prolonged plasma  exposure                                                                                                  
                                                                                         and diminished drug toxicity 
 
A G5 conjugate of FA-PAMAM-MTX was 
investigated for the targeted delivery of 
methotrexate, the conjugate demonstrated 
high specificity for KB cells over expressing 
folate receptors and showed sustained drug 
release (Patri et al., 2005)  
 
The authors further conjugated the PhiPhiLux 
G1 D2, an apoptotic sensor to FA attached 
PAMAM dendrimers and  this showed an  
enhanced fluorescence, attributed to 
successful delivery of drug with higher cell 
killing efficacy ( Myc et al., 2007). FA 
conjugated G5 PAMAM dendrimers 
successfully delivered 2 methoxyestradiol to 
targeted cancer cells, as confirmed by MTT 
assay (Wang et al., 2011). A folate 
functionalized PEG coated nanocarriers based 
on fourth generation diaminobutane PPI 
dendrimer was evaluated for targeted delivery 
of etoposide. The encapsulation of the drug 
inside the dendrimeric scaffold resulted in 
enhanced solubility of etoposide and the in-
vitro release of encapsulated drug from this 
functional dendrimer was found to be 
sustained and comparable to the non-
functionalized dendrimers. These folate 
PEGylated dendrimers exhibited specificity for 
folate receptors with low toxicity (Sideratou et 
al., 2010). Lastly, successful conjugation of FA 
to fifth generation PPI dendrimers was 
explored and its potential in targeted delivery 
of an anticancer drug doxorubicin was 
investigated. The results revealed that FA 
conjugated dendrimers displayed higher cell 
uptake in MCF-7 cancer cell lines and 




Potentials of dendrimers as vehicles for site-
specific delivery of anti-cancer drugs seems to 
be promising. Dendrimers will be expected to 
keep playing key role in biomedical, and 
pharmaceutical fields as they provide an 
excellent platform for drug conjugation and 
have the ability to encapsulate or bind different 
drugs via several mechanisms such as 
physical encapsulation and electrostatic 
interaction. Their high costs, complex 
synthesis procedure and toxicity issues are 
however few drawbacks.. 
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